title: Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
authors.forename: J L
authors.initials: JL
authors.lastname: Miller
mesh_terms: D004341:Drug Evaluation / Q000592:standards*; D004335:Drug and Narcotic Control / Q000706:statistics & numerical data*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D006801:Humans; D011358:Product Surveillance, Postmarketing / Q000592:standards*; D012308:Risk Management; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards*